Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author GENEROSO, Giuliano FMUSP-HC
BENSENOR, Isabela M. FMUSP-HC
SANTOS, Raul D. FMUSP-HC
SANTOS, Itamar S. FMUSP-HC
GOULART, Alessandra C. FMUSP-HC
JONES, Steven R.
KULKARNI, Krishnaji R.
BLAHA, Michael J.
TOTH, Peter P.
LOTUFO, Paulo A. FMUSP-HC
BITTENCOURT, Marcio Sommer FMUSP-HC
dc.date.issued 2018
dc.identifier.citation JOURNAL OF CLINICAL LIPIDOLOGY, v.12, n.5, p.1290-1297, 2018
dc.identifier.issn 1933-2874
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/29822
dc.description.abstract BACKGROUND: High-density lipoprotein cholesterol (HDL-C) can be divided into subfractions, which may have variable effects in atherogenesis. The results about the association between HDL-C subfractions and risk factors for cardiovascular disease are mixed. OBJECTIVE: The objective of this study was to analyze the association between HDL-C subfractions and each metabolic syndrome component, homeostasis model assessment-estimated insulin resistance (HOMA-IR) and C-reactive protein (CRP). METHODS: Four thousand five hundred thirty-two individuals between 35 and 74 years old without previous manifest cardiovascular disease not using fibrates were enrolled. HDL-C subfractions were separated by vertical ultracentrifugation (vertical auto profile-in mg/dL) into HDL2-C and HDL3-C. HDL2-C/HDL3-C ratio, HOMA-IR, and high-sensitivity CRP were also included in the analysis. RESULTS: Mean age of participants was 51 +/- 9 years, and 54.8% were women. In univariate analysis, HDL-C, HDL2-C, and HDL3-C were all inversely associated with each of the metabolic syndrome defining factors, HOMA-IR values, and serum CRP. We also observed a negative association between HDL2-C/HDL3-C ratio with the variables aforementioned even after adjusting for smoking, alcohol use, physical activity, and HDL-C levels (P < .01). CONCLUSION: HDL-C and its subfractions (HDL2-C and HDL3-C) are inversely associated with the defining features of metabolic syndrome, insulin resistance, and systemic inflammation. In addition, the HDL2-C/HDL3-C ratio measured by vertical auto profile is significantly associated with the former factors even after comprehensive adjustment for HDL-C and other confounding variables.
dc.description.sponsorship · Brazilian Ministry of Health (Science and Technology Department)
· Brazilian Ministry of Science and Technology (Financiadora de Estudos e Projetos)
· Brazilian Ministry of Science and Technology (CNPq National Research Council) [01 06 0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01 06 0115.00 SP, 01 06 0071.00 RJ]
dc.language.iso eng
dc.publisher ELSEVIER SCIENCE INC
dc.relation.ispartof Journal of Clinical Lipidology
dc.rights restrictedAccess
dc.subject High-density lipoprotein subfractions; Insulin resistance; Low-grade inflammation; Metabolic syndrome
dc.subject.other dependent diabetes-mellitus; cardiovascular-disease; myocardial-infarction; hdl-cholesterol; lipase activity; high-risk; subclasses; mortality; events; men
dc.title Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study
dc.type article
dc.rights.holder Copyright ELSEVIER SCIENCE INC
dc.description.group LIM/51
dc.description.group LIM/20
dc.identifier.doi 10.1016/j.jacl.2018.05.003
dc.identifier.pmid 29941395
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author GENEROSO, Giuliano:HC:INCOR
hcfmusp.author BENSENOR, Isabela M.:FM:MCM
hcfmusp.author SANTOS, Raul D.:FM:MCP
hcfmusp.author SANTOS, Itamar S.:FM:MCM
hcfmusp.author GOULART, Alessandra C.:HU:SCPACEX-62
hcfmusp.author LOTUFO, Paulo A.:FM:MCM
hcfmusp.author BITTENCOURT, Marcio Sommer:HC:ICESP
hcfmusp.author.external · JONES, Steven R.:Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA
· KULKARNI, Krishnaji R.:VAP Diagnost Lab, Birmingham, AL USA
· BLAHA, Michael J.:Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA
· TOTH, Peter P.:Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA; CGH Med Ctr, Prevent Cardiol, Sterling, IL USA
hcfmusp.origem.id WOS:000447815400030
hcfmusp.origem.id 2-s2.0-85048886031
hcfmusp.publisher.city NEW YORK
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Albers JJ, 2016, ATHEROSCLEROSIS, V251, P454, DOI 10.1016/j.atherosclerosis.2016.06.019
· Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
· Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
· Ashby DT, 1998, ARTERIOSCL THROM VAS, V18, P1450, DOI 10.1161/01.ATV.18.9.1450
· BAGDADE JD, 1993, ATHEROSCLEROSIS, V104, P69, DOI 10.1016/0021-9150(93)90177-V
· Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628
· Berthold HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091565
· DREXEL H, 1992, AM J CARDIOL, V70, P436, DOI 10.1016/0002-9149(92)91186-8
· Fedeli LG, 2013, REV SAUDE PUBL, V47, P63, DOI 10.1590/S0034-8910.2013047003807
· Hafiane A, 2015, BBA CLIN, V3, P175, DOI 10.1016/j.bbacli.2015.01.005
· Holmes MV, 2015, EUR HEART J, V36, P539, DOI 10.1093/eurheartj/eht571
· HPS3 TIMI55-REVEAl Collaborative, 2017, NEW ENGL J MED, V377, P1217, DOI 10.1056/NEJMoa1706444
· Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683
· Joshi PH, 2016, EUR J PREV CARDIOL, V23, P41, DOI 10.1177/2047487314543890
· Kardassis D, HDB EXPT PHARM, V224, DOI [10.1007/978-3-319-09665-0, DOI 10.1007/978-3-319-09665-0]
· Kaur J, 2014, CARDIOL RES PRACT, DOI 10.1155/2014/943162
· Kim DS, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000902
· Kulkarni KR, 2006, CLIN LAB MED, V26, P787, DOI 10.1016/j.cll.2006.07.004
· Lagos KG, 2009, LIPIDS, V44, P9, DOI 10.1007/s11745-008-3251-9
· Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709
· Landray MJ, 2014, NEW ENGL J MED, V371, P203, DOI 10.1056/NEJMoa1300955
· Mann DL, 2015, BRAUNWALDS HEART DIS, P980
· Martin SS, 2015, EUR HEART J, V36, P22, DOI 10.1093/eurheartj/ehu264
· MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
· Mooradian AD, 2004, DIABETES, V53, P513, DOI 10.2337/diabetes.53.3.513
· Navab M, 2011, NAT REV CARDIOL, V8, P222, DOI 10.1038/nrcardio.2010.222
· Nicholls SJ, 2011, JAMA-J AM MED ASSOC, V306, P2099, DOI 10.1001/jama.2011.1649
· Patel DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022142
· Pereira AC, 2013, REV SAUDE PUBL, V47, P72, DOI 10.1590/S0034-8910.2013047003822
· Rashid S, 2003, CLIN BIOCHEM, V36, P421, DOI 10.1016/S0009-9120(03)00078-X
· Rizzo M, 2008, ATHEROSCLEROSIS, V200, P389, DOI 10.1016/j.atherosclerosis.2007.12.020
· SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129
· Schmidt MI, 2015, INT J EPIDEMIOL, V44, P68, DOI 10.1093/ije/dyu027
· Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797
· STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601
· Superko HR, 2012, J CLIN LIPIDOL, V6, P496, DOI 10.1016/j.jacl.2012.03.001
· Tang CR, 2010, J LIPID RES, V51, P1719, DOI 10.1194/jlr.M003525
· Vieira BA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163044
· WILLIAMS PT, 1992, ARTERIOSCLER THROMB, V12, P332, DOI 10.1161/01.ATV.12.3.332
· WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737
· YOST TJ, 1995, METABOLISM, V44, P786, DOI 10.1016/0026-0495(95)90193-0
dc.description.index MEDLINE
dc.identifier.eissn 1876-4789
hcfmusp.citation.scopus 1
hcfmusp.citation.wos 1
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Estados Unidos


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics